NovoCure FY2025 EPS Estimate Increased by Leerink Partnrs

NovoCure Limited (NASDAQ:NVCR) – Investment analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for shares of NovoCure in a research note issued to investors on Monday, December 2nd. Leerink Partnrs analyst J. Chang now expects that the medical equipment provider will post earnings per share of ($1.92) for the year, up from their prior estimate of ($1.93). The consensus estimate for NovoCure’s current full-year earnings is ($1.31) per share.

Several other research firms also recently weighed in on NVCR. Evercore ISI raised NovoCure from an “in-line” rating to an “outperform” rating and lifted their target price for the company from $18.00 to $30.00 in a research report on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $38.00 price objective (up from $30.00) on shares of NovoCure in a research report on Monday, December 2nd. Finally, Wedbush reissued a “neutral” rating and set a $29.00 price objective (up from $24.00) on shares of NovoCure in a research report on Monday, December 2nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $30.33.

NovoCure Stock Performance

NASDAQ NVCR opened at $27.96 on Thursday. The company has a market cap of $3.03 billion, a P/E ratio of -19.97 and a beta of 0.75. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.49 and a quick ratio of 1.44. The stock has a 50-day moving average of $17.93 and a two-hundred day moving average of $18.67. NovoCure has a 1-year low of $11.66 and a 1-year high of $32.60.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. The firm had revenue of $155.10 million during the quarter, compared to the consensus estimate of $143.95 million. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The company’s quarterly revenue was up 21.8% on a year-over-year basis. During the same period last year, the company earned ($0.46) EPS.

Institutional Investors Weigh In On NovoCure

Several institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its stake in NovoCure by 222.6% during the third quarter. Franklin Resources Inc. now owns 180,853 shares of the medical equipment provider’s stock worth $2,904,000 after purchasing an additional 124,793 shares during the last quarter. Tidal Investments LLC lifted its stake in NovoCure by 4.6% during the third quarter. Tidal Investments LLC now owns 55,756 shares of the medical equipment provider’s stock worth $871,000 after purchasing an additional 2,465 shares during the last quarter. Geode Capital Management LLC lifted its stake in NovoCure by 1.3% during the third quarter. Geode Capital Management LLC now owns 2,405,257 shares of the medical equipment provider’s stock worth $37,601,000 after purchasing an additional 29,871 shares during the last quarter. Weiss Asset Management LP purchased a new stake in NovoCure during the third quarter worth approximately $735,000. Finally, IHT Wealth Management LLC purchased a new stake in NovoCure during the third quarter worth approximately $180,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.